Shanghai Longwood Biopharmaceuticals

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
JAK1Small molecule
Atopic Dermatitis
Phase 1/2
—
Chronic Hepatitis B

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
LW231Phase 1/2Chronic HBV Infection
Est. primary completion 2027-03 · NCT07179575 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
LW402Phase 2Non-Segmental Vitiligo (NSV)
Est. primary completion 2028-02-01 · NCT07556471 · CT.gov ↗
What to watch
March 2028 (1)
LW402Phase 3Moderate to Severe Atopic Dermatitis
Est. primary completion 2028-03-31 · NCT07370909 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.